ATE209492T1 - Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen - Google Patents

Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen

Info

Publication number
ATE209492T1
ATE209492T1 AT98924313T AT98924313T ATE209492T1 AT E209492 T1 ATE209492 T1 AT E209492T1 AT 98924313 T AT98924313 T AT 98924313T AT 98924313 T AT98924313 T AT 98924313T AT E209492 T1 ATE209492 T1 AT E209492T1
Authority
AT
Austria
Prior art keywords
triazolo
treatment
production
cerebrovascular disorders
medicinal products
Prior art date
Application number
AT98924313T
Other languages
German (de)
English (en)
Inventor
Ennio Ongini
Marina Adami
Rosalia Bertorelli
Original Assignee
Schering Plough S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough S P A filed Critical Schering Plough S P A
Application granted granted Critical
Publication of ATE209492T1 publication Critical patent/ATE209492T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98924313T 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen ATE209492T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
PCT/EP1998/002852 WO1998052568A1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES

Publications (1)

Publication Number Publication Date
ATE209492T1 true ATE209492T1 (de) 2001-12-15

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924313T ATE209492T1 (de) 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen

Country Status (9)

Country Link
EP (1) EP0983068B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2002502370A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1255854A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE209492T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU740475B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2289847A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69802679D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1291372B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1998052568A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028621A1 (es) * 2000-05-26 2003-05-14 Schering Corp Antagonistas receptores de adenosina a2a
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CA2430328A1 (en) * 2001-09-28 2003-04-10 Kyowa Hakko Kogyo Co., Ltd. Receptor antagonist
US6653315B2 (en) 2001-10-15 2003-11-25 Schering Corporation Adenosine A2a receptor antagonists
EP1448565B1 (en) 2001-11-30 2009-12-30 Schering Corporation ADENOSINE A2a RECEPTOR ANTAGONISTS
EP1453836B1 (en) 2001-11-30 2007-03-28 Schering Corporation BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
JP4527712B2 (ja) 2003-04-23 2010-08-18 シェーリング コーポレイション ２−アルキニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニストおよび２−アルケニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニスト
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
EP1888534B1 (en) 2005-06-06 2017-07-26 Intra-Cellular Therapies, Inc. Organic compounds
EP1934227B1 (en) 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
EP2023729B1 (en) 2006-06-06 2016-05-04 Intra-Cellular Therapies, Inc. Organic compounds
US9198924B2 (en) 2006-11-13 2015-12-01 Intra-Cellular Therapies, Inc. Organic compounds
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
CN101969774A (zh) 2007-12-06 2011-02-09 细胞内治疗公司 有机化合物
US8222259B2 (en) 2008-03-04 2012-07-17 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
WO2010009190A1 (en) * 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
BRPI0922348A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
MA32940B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EP2358204B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US10561656B2 (en) 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
JP2016518343A (ja) 2013-03-15 2016-06-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US9073936B2 (en) 2013-03-15 2015-07-07 Intra-Cellular Therapies, Inc. Organic compounds
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
US10472347B2 (en) 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
KR102562576B1 (ko) 2014-12-06 2023-08-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US10138212B2 (en) 2015-02-06 2018-11-27 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as A2A antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
WO2019152697A1 (en) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Novel uses
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Also Published As

Publication number Publication date
DE69802679D1 (de) 2002-01-10
EP0983068A1 (en) 2000-03-08
EP0983068B1 (en) 2001-11-28
WO1998052568A1 (en) 1998-11-26
ITMI971190A1 (it) 1998-11-21
ITMI971190A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-05-21
AU7654698A (en) 1998-12-11
CA2289847A1 (en) 1998-11-26
AU740475B2 (en) 2001-11-08
IT1291372B1 (it) 1999-01-07
CN1255854A (zh) 2000-06-07
JP2002502370A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
ATE209492T1 (de) Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
TW200500344A (en) Novel compounds
IL132153A0 (en) Novel compounds
HU896762D0 (en) Process for preparation of pyrimidine-derivatives and for manufacturing of pharmaceutical compositions containing these compounds
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
FI904204A0 (fi) Foerfarande foer framstaellning av cykliska aminosyraderivat och mellanprodukter.
HUT70505A (en) Pyrrolo[2,3-d]pyrimidine derivatives, pharmaceutical compositions containing them and process for preparing them
AU5501598A (en) Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
UA93047C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[3,4-d]АЗЕПИНА КАК АНТАГОНИСТЫ H3-РЕЦЕПТОРОВ ГИСТАМИНА
SE9904129D0 (sv) Novel compounds
DE3583220D1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten.
DE69320349D1 (de) Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen
MY131024A (en) Immunostimulating 6-aryl-5, 6-dihydroimidazo [2,1-b] thiazole derivatives.
ATE240116T1 (de) Verwendung von human-beta-interferon zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von chronischer myeloidleukämie
DE69927251D1 (de) Verfahren zur herstellung von purinderivaten und dessen zwischenprodukte
UY24717A1 (es) Nuevo tratamiento
ATE334680T1 (de) 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
EP0812844A3 (de) Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
ATE44743T1 (de) 4-oxo-pyrido(2,3>pyrimidin-derivate, verfahren zur deren herstellung und diese ethaltende arzneimittel.
ES2165792A1 (es) "oligomeros de bloque conteniendo grupos 1-hidrocarbiloxi-2,2,6,6-tetrametil-4-piperidilo como estabilizadores para materiales organicos"
ATE210665T1 (de) Zwischenprodukte und verfahren zur herstellung von 5,6-dihydropyrrolo(2,3-d)pyrimidinen
SV1994000072A (es) Nuevo compuesto rac-4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetilpiridin-3,5-dicarboxilato de isopropilo y 2-metoxietilo ref. le a 30 548-sv